Minoxidil vs Finasteride vs Hair Growth Peptides — What the Research Actually Says

Hair loss treatment is a market dominated by hope, and marketers exploit that hope aggressively. Two treatments have the most robust clinical evidence: minoxidil and finasteride. A third category — peptide-based actives — has emerged with credible early trial data and growing consumer adoption. Understanding the mechanism, evidence base, and risk profile of each treatment enables rational decision-making that isn't driven by brand marketing or anecdote. This article provides that foundation. Note: this is educational information, not medical advice. Consult a dermatologist or trichologist before starting any hair loss treatment.

Minoxidil: The OG Vasodilator

Minoxidil was discovered as a hair growth treatment accidentally during clinical trials of an oral antihypertensive. Applied topically, it is converted by the enzyme sulphotransferase in scalp tissue to its active metabolite, minoxidil sulphate. This metabolite opens ATP-sensitive potassium channels (KATP channels) in vascular smooth muscle cells surrounding hair follicles, causing relaxation and vasodilation. The resulting increase in local blood flow delivers more nutrients and oxygen to the metabolically demanding hair matrix cells.

Beyond vascular effects, minoxidil has direct effects on hair follicle biology. It appears to upregulate prostaglandin endoperoxide synthase-1 (PTGS-1/COX-1) and prostaglandin E2 (PGE2), which promotes hair growth independently of blood flow. It also shortens the telogen (resting) phase and extends anagen (growth) duration. Critically, minoxidil does not inhibit DHT — it does not address the underlying cause of androgenetic alopecia, but rather compensates for its effects.

2% vs 5% Topical Minoxidil

FDA-approved at 2% for women and 5% for men with androgenetic alopecia, both concentrations produce clinically meaningful hair regrowth. A head-to-head comparison published in the Journal of the American Academy of Dermatology found 5% topical minoxidil produced significantly greater hair count increases than 2% at 48 weeks in men. For women, 5% minoxidil shows superior efficacy but carries a higher risk of unwanted facial hair growth (hypertrichosis) — hence the 2% regulatory approval for women, though dermatologists commonly prescribe 5% off-label.

Topical vs Oral Minoxidil

Oral minoxidil at low doses (0.625–2.5 mg/day, far below cardiovascular doses of 5–40 mg) has gained significant clinical traction as an alternative to topical application. Multiple retrospective and prospective studies show oral minoxidil produces comparable or superior hair density improvements to topical application, with better tolerability in patients who experience topical scalp irritation or allergic contact dermatitis. The systemic side effect profile — primarily fluid retention, tachycardia, and hypertrichosis — requires cardiovascular screening before initiation, making it a prescription-only option with medical oversight.

ROGAINE

Rogaine Men's 5% Minoxidil Foam

FDA APPROVED

• —FDA-approved 5% minoxidil foam formulation
• —Once daily application (easier adherence than twice-daily solution)
• —Alcohol-free foam reduces scalp dryness vs solution format
• —Clinically proven to regrow hair at vertex/crown in male pattern baldness
• —3-month supply per pack — standard assessment period

Rogaine 5% foam is the gold-standard topical minoxidil formulation for men. The once-daily foam format significantly improves adherence over the original twice-daily solution. Realistic results require 4–6 months of consistent use before meaningful assessment.

Shop Rogaine 5% Foam on Amazon →

Finasteride: The DHT Blocker

Finasteride targets androgenetic alopecia at its root cause — DHT production. It works by inhibiting 5-alpha reductase type II, the enzyme that converts testosterone to dihydrotestosterone (DHT) in scalp tissue and the prostate. At the FDA-approved oral dose of 1 mg/day, finasteride reduces scalp DHT levels by approximately 60–70%. This prevents the progressive miniaturisation of genetically susceptible follicles, the underlying biological process in male pattern baldness.

Efficacy data for finasteride is among the strongest in any hair loss treatment: multiple large randomised controlled trials show 83% of men maintaining or increasing hair count at 2 years (vs 28% of placebo), with mean hair count increases of 100+ hairs/cm² in the target zone over 5 years of treatment. Crucially, finasteride effects are maintenance-dependent — discontinuing treatment reverses gains within 12 months as DHT returns to baseline levels.

The Side Effect Profile: A Balanced View

Finasteride's side effect profile requires honest discussion. Clinical trials report sexual adverse effects (decreased libido, erectile dysfunction, ejaculatory dysfunction) in 1.8–3.8% of patients. A small subset of patients (estimates vary from 0.3% to 1.5%) report persistent sexual side effects after discontinuation — Post-Finasteride Syndrome (PFS). The PFS literature is contested due to heterogeneous reporting and the difficulty of establishing causation, but the condition is real for affected individuals. Finasteride is absolutely contraindicated in women who are pregnant or may become pregnant due to risk of external genitalia feminisation in male fetuses.

Hair Growth Peptides: The Evidence-Based Alternatives

Peptide-based actives represent the fastest-growing segment of the cosmeceutical hair loss market. Unlike minoxidil (which requires enzymatic activation) and finasteride (which requires systemic distribution), these topical compounds are designed to act directly at the follicle interface. The most studied include:

• Redensyl: A combination of dihydroquercetin-glucoside (DHQG) and epigallocatechin-gallate-glucoside (EGCG2) that targets the LRIG1 stem cell marker in the follicle bulge. A published randomised controlled trial showed Redensyl produced 17% more hair density increase than minoxidil 5% over 84 days in men with androgenetic alopecia — though sample sizes were small (26 subjects).
• Procapil: A combination of biotinyl tripeptide-1, apigenin, and oleanolic acid that targets three separate mechanisms: follicle cell anchoring, DHT inhibition at the follicle level, and improved scalp circulation. Clinical data from the manufacturer shows 121% decrease in hair loss vs placebo at 28 days.
• Capixyl: Biotinoyl tripeptide-1 combined with red clover extract. Targets the same LRIG1 stem cell pathway as Redensyl with additional androgenic inhibition. Manufacturer data shows 46% reduction in hair loss and 35% increase in hair density vs placebo, though independent replication is limited.
• Baicapil: A combination of Scutellaria baicalensis stem cells, wheat, and soy that claims to improve keratinocyte proliferation and follicle anchoring. Manufacturer data shows 52% reduction in hair loss vs placebo.

THE

The Ordinary Multi-Peptide Serum for Hair Density

BEST VALUE PEPTIDES

• —Contains Redensyl, Procapil, Capixyl, VEGF peptides in one formula
• —Alcohol-free, suitable for sensitive scalps
• —Lightweight serum absorbs without residue
• —One of the highest-concentration peptide blends available OTC
• —Approximately $17 — exceptional active ingredient value

The Ordinary's Multi-Peptide Serum stacks Redensyl + Procapil + Capixyl at effective concentrations in a single, alcohol-free formula. For consumers who want the full peptide stack without multiple products, this is the most cost-efficient entry point with a credible formulation.

Shop The Ordinary Serum on Amazon →

Decision Framework: Which Treatment for You

For men with androgenetic alopecia, the evidence-based first-line combination remains topical minoxidil + oral finasteride (where appropriate after medical evaluation). Peptide serums add incremental benefit with very low risk as an adjunct layer. For women, or men who cannot take finasteride, topical minoxidil + peptide stack represents the best evidence-supported non-prescription approach. Consult a dermatologist for personalised treatment selection.